3aZEVvoRtp6McXy8TuIlR6lERn067Z

Investor Relations

NYSE: NVRO

Price

80.76 -0.03 ( -0.04% ) 4:02 8/16/19 Pricing delayed 20 minutes

Volume 339,155

Recent News

See All
August 8, 2019 Nevro Reports Second Quarter 2019 Financial Results
Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today reported financial results for the second quarter ended June 30, 2019. Revenue for the second quarter of 2019 was $93.6 million, a 3% decrease compared to $96.1 million during the prior year period. U.S. revenue for the second quarter of 2019 was $78.1 million, a 2% decrease compared to $79.9 million in the prior year period. The year-over-year decrease in U.S. revenue was primarily driven by the impact of customer destocking associated with the Company's previously announced decision to alter its practice regarding certain high-volume product orders.  International revenue was $15.5 million compared to $16.2 million in the prior year period. This represents a 4% decrease on an as-reported basis and a 2% increase on a constant currency basis. "Our second quarter 2019 financial results demonstrate sequential improvement across the...
July 25, 2019 Nevro Announces Court Order Granting Preliminary Injunction Against Stimwave Technologies, Inc.
Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today announced that U.S. District Judge Colm Connolly, in the District of Delaware, granted Nevro's motion for preliminary injunction, and has issued an order barring Stimwave Technologies, Inc., and all affiliated persons and entities, from infringing patent claims covering frequencies between 3 kHz and 10 kHz by programming Stimwave's SCS systems to deliver its recently introduced high-frequency, paresthesia-free SCS therapy.  Per Nevro's request, the court order does not enjoin Stimwave from providing follow-up care and programming for any patients who were already programmed with such high frequency therapy. "Protecting our core intellectual property has always been important to Nevro's success as a business, and today's order affirms once again the strength of our intellectual property," said Kashif Rashid, General Counsel for Nevro....
July 15, 2019 ­Nevro to Report Second Quarter 2019 Financial Results
Company to Host Conference Call on Thursday, August 8, 2019 at 1:30 p.m. PT / 4:30 p.m. ET Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that the Company will release its financial results for the second quarter ended June 30, 2019 after the market closes on August 8, 2019. Investors interested in listening to the conference call may do so by dialing (833) 286-5807 in the U.S. or (647) 689-4452 internationally, using Conference ID: 1694716.  In addition, a live webcast, as well as an archived recording, will be available on the "Investors" section of the Company's website at: www.nevro.com. About Nevro Corp.
Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the...

About Nevro

Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the SENZA® spinal cord stimulation (SCS) system, an evidence-based, non-pharmacologic neuromodulation platform for the treatment of chronic pain. The SENZA® system is the only SCS system that delivers Nevro's proprietary HF10™ therapy. Senza, Senza II, HF10, Nevro and the Nevro logo are trademarks of Nevro.

Senza, Senza II, HF10, More, Nevro, Nevrocloud, Surpass and the Nevro, HF10, and Frequency Pairing Logos are trademarks of Nevro Corp.